Zwart-van Rijkom, J.E.F.

abciximab patient stent survival stenting month fficacy result procedure revascularization infarction mace-free e ffects diabetic 6 months study epistent angioplasty trial cost-e non-diabetic mi-free e fficacy balloon angioplasty survivor difference cost-e fficacy ratios eur heart j epistent study estimate heart value number event ptca +abciximab arm fi rst place cost-e fficacy stent +placebo arm stent implantation platelet combination /iiia zwart-van rijkom analysis balloon netherland e ffect question implantation fference fi rst month probability mi =myocardial infarction investigator –1000 infarction-free –25 –20 limit mace-free survival unit costs infarction-free survival –2000 ellipse decrease –15 –10 di fferences stent procedure issue fi nding –3000 ratio event-free european restenosi comparison group <0·001 /abciximab